

Title: Incorporating TKI Therapy into CML Management

Dates: November 23, 2015 – November 23, 2017

Locations: http://www.mycmesite1.com/index.aspx?case_id=564

Learning Objectives:

ASSESS the efficacy, safety, and guideline indications for various CML TKI therapy options.

EVALUATE cytogenetic and molecular tests as tools to individualize patient management plans.

DESCRIBE guideline and evidenced-based data regarding CML therapy adjustments vis-à-vis time-based clinical responses.

Target Audience: These case modules are designed for medical oncologists, hematologists, hematologist/oncologists, and oncology nurses/advanced practitioners. No prerequisites required.

Program Overview: The advent of tyrosine kinase inhibitor (TKI) therapy that targets the oncogenic BCR-ABL protein has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires long-term pharmacological disease management. Monitoring patient response to TKI therapy at recommended time intervals is the cornerstone of patient management and is an important milestone for predicting long-term treatment outcome. The National Comprehensive Cancer Network (NCCN) therapy recommendations for first-line TKIs include first-generation imatinib or second-generation nilotinib or dasatinib. These interactive case studies will review the NCCN guidelines for TKI therapy for treating high- and low-risk patients and will also address the considerations necessary for choosing the best treatment plan, including risk stratification of patients, pregnancy, patients who do not meet their milestones, and if, when, and how to switch therapy.

Faculty:

Javier Pinilla-Ibarz, MD, PhD
Associate Member
Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education



(ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and ASiM. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement:

Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support: This activity is supported by an independent educational grant from Bristol-Myers Squibb.

